Nuvation Bio, Inc. Class A (NUVB)

Over the past six months, Nuvation Bio's stock price has been influenced by analyst sentiment and price target adjustments, with Truist Securities reaffirming a "Buy" rating and RBC raising its price target. The EMA validated a Marketing Authorisation Application for taletrectinib, which was seen as a positive catalyst. Q4 2025 financial results revealed revenue exceeding expectations but a wider-than-anticipated loss, and the disclosure of later-line treatment settings impacting revenue growth led to a stock price drop. The Chief Regulatory Officer sold 200,000 shares of NUVB stock. The stock has also been affected by broader biotech sector performance and macro crosscurrents.

Information explicitly detailing demand seasonality for Nuvation Bio's products and services is not extensively provided. However, the CEO indicated that it is "hard to predict a bounce back from Q4 seasonality" in the context of revenue, suggesting some level of revenue seasonality might exist. Significant inherent seasonality in patient demand for these critical treatments is generally less pronounced compared to consumer goods or seasonal services.

Nuvation Bio, Inc. is a global oncology biopharmaceutical company focused on developing novel therapeutic candidates to address unmet needs in cancer treatment. The company operates in the Healthcare sector, specifically in the Biotechnology industry. Its portfolio includes oncology product candidates such as IBTROZI (taletrectinib), safusidenib, NUV-1511, and NUV-868. Nuvation Bio generates revenue from product sales, upfront license fees, royalty revenue, and research and development services from out-licensing collaborative agreements.

Nuvation Bio is dual-headquartered in New York, NY, and San Francisco, CA, with additional offices in Boston and Shanghai. The company has a global reach through its product development and commercialization efforts. IBTROZI has received FDA approval in the U.S., and the company has secured licensing deals for its distribution in Europe and other ex-U.S. markets with Eisai. Nuvation Bio also generates a majority of its revenue from Japan.

Nuvation Bio's brand reputation has seen both positive developments and challenges in the past year. The rapid adoption of IBTROZI following FDA approval has been a strong positive. However, the Q4 2025 earnings report, which disclosed that a significant portion of early IBTROZI patient starts were in later-line treatment settings, leading to higher discontinuation rates and impacting revenue growth, resulted in a substantial drop in stock price and triggered investigations by law firms.

Nuvation Bio's ownership structure includes institutional, insider, and public/individual investors. Approximately 36.06% to 45.37% of the company's stock is owned by institutional investors, 24.92% by insiders, and 9.31% to 29.72% by public companies and individual investors. David Hung, the company's founder, owns a significant portion of Nuvation Bio shares. Major institutional shareholders include Fmr Llc, Decheng Capital LLC, BlackRock, Inc., Vanguard Group Inc, Omega Fund Management, LLC, Laurion Capital Management LP, State Street Corp, Geode Capital Management, Llc, Tang Capital Management Llc and Abrams Capital Management, L.p.